SCHEMBL3415674

SCHEMBL3415674

CC(C)(C)OCc1cccc(-c2ccc(N)nc2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.53
TNIK Q9UKE5 2/20 0.40
AGXT P21549 3/20 0.40
ALOX5AP P20292 1/20 0.39
FYN P06241 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
PIK3CD O00329 3/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
INPPL1 O15357 1/20 0.38
ATM Q13315 1/20 0.37
MPO P05164 1/20 0.37
BACE1 P56817 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431287 0.83 MAP4K4 (0.49) MAP4K4TNIKAGXTALOX5APFYN
SCHEMBL12305044 0.79 MAP4K4 (0.62) MAP4K4TNIKFYNCYP4F2CYP4A11
SCHEMBL28795779 0.78 EPHX2 (0.57) BACE1
SCHEMBL3409528 0.76 SYK (0.44) CYP4F2CYP4A11PIK3CD
SCHEMBL3410543 0.76 MAP4K4 (0.62) MAP4K4TNIKFYNPIK3CDDYRK1A
SCHEMBL12253728 0.73 MAP4K4 (0.62) MAP4K4TNIKALOX5APPIK3CDDYRK1A
SCHEMBL29711705 0.73 MAP4K4 (0.62) MAP4K4TNIKALOX5APPIK3CDDYRK1A
SCHEMBL646850 0.73 IDO1 (0.42) AGXTPRMT5WDR77
SCHEMBL13046918 0.72 MAOB (0.47) AGXT
SCHEMBL20350158 0.72 PRMT5 (0.42) AGXTPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN MAP4K4 2969/4885TNIK 4125/4885AGXT 203/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN MAP4K4 2969/4885TNIK 4125/4885AGXT 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.